Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cassava Sciences Inc
(NQ:
SAVA
)
23.12
+1.56 (+7.24%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Cassava Sciences Inc
< Previous
1
2
...
12
13
14
15
16
17
18
19
Next >
12 Health Care Stocks Moving In Friday's Intraday Session
September 24, 2021
Gainers Molecular Templates (NASDAQ:MTEM) stock rose 14.13% to $7.59 during Friday's regular session. Trading volume for Molecular Templates's stock is 937.9K as...
Via
Benzinga
58 Biggest Movers From Yesterday
September 24, 2021
Gainers MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) shares surged 73.4% to close at $12.80 on Thursday following news the company will buy ZACC Kabushiki Kaisha for $3.362...
Via
Benzinga
Why Shares of Cassava Sciences Rose 15% Today
September 23, 2021
Additional data is promising. But will investors trust it?
Via
The Motley Fool
B. Riley Says Alzheimer's Data From This Firm Has Renewed 'Investor Confidence'
September 23, 2021
B. Riley says yesterday's readout from a pre-planned 12-month treatment interim analysis of Cassava Sciences Inc's (NASDAQ: SAVA) simufilam trial data...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
September 23, 2021
Gainers TransCode Therapeutics (NASDAQ:RNAZ) stock rose 94.3% to $5.09 during Thursday's regular session. TransCode Therapeutics's stock is trading at a volume of...
Via
Benzinga
SAVA Stock: What Is Going on With Red-Hot Cassava Sciences Today?
September 22, 2021
Today, Cassava Sciences initially soared on the announcement of some positive preliminary data, before SAVA stock began selling off.
Via
InvestorPlace
The Cassava Sciences Saga Rages On — Why This Alzheimer's Update Didn't Save It
September 22, 2021
Cassava said patients who received its Alzheimer's drug showed improved cognition.
Via
Investor's Business Daily
Cassava Sciences' Simufilam Data Shows Improved Cognition In Alzheimer's Disease
September 22, 2021
Cassava Sciences Inc (NASDAQ: SAVA) has announced top-line data from a pre-planned interim analysis of an ongoing open-label study of simufilam in mild-to-moderate...
Via
Benzinga
Cassava Sciences Can Recover Despite Harsh Allegations
September 21, 2021
SAVA stock dove after a law firm made statements against the company. However, Cassava's CEO isn't just taking it lying down.
Via
InvestorPlace
The Cassava Saga: Here's What You Need To Know About This Embattled Alzheimer's Stock
September 21, 2021
Cassava Sciences could hold the holy grail in Alzheimer's treatment. But once highflying SAVA stock has plummeted in a firestorm this year.
Via
Investor's Business Daily
Cassava Sciences Has Value and Is Likely To Proceed to Phase 3
September 17, 2021
SAVA stock still has an implied upside of 67.9% to $78 per share, even if there is a 50% chance that either the shorts or longs are right.
Via
InvestorPlace
46 Biggest Movers From Yesterday
September 15, 2021
Gainers Communications Systems, Inc. (NASDAQ: JCS) jumped 39.4% to close at $9.41 on Tuesday as the company declared a special dividend of $3.50 per share. Onion Global Limited...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
September 14, 2021
Gainers Progenity (NASDAQ:PROG) shares increased by 17.0% to $1.1 during Tuesday's regular session. As of 12:30 EST, this security is trading at a volume of 40.5...
Via
Benzinga
36 Stocks Moving In Tuesday's Mid-Day Session
September 14, 2021
Gainers FuelCell Energy, Inc. (NASDAQ: FCEL) shares jumped 26% to $7.08 after the company reported better-than-expected Q3 results. BELLUS Health Inc. (NASDAQ: BLU) shares...
Via
Benzinga
Cassava Stock Is a Bold Play That Could Pay Off Soon
September 13, 2021
Bears are attacking SAVA stock as it questions the quality of its clinical data and try to stop its study for treating Alzheimer’s disease.
Via
InvestorPlace
A Reply To Dr Biks on $SAVA PTau-181
September 11, 2021
Data by BruinAnteater @BruinStocks - Twitter, @BruinAnteaterStock - Stocktwits A Quick Introduction Hello, allow me to introduce myself. On twitter I am known as @BruinStocks, and...
Via
Benzinga
What Happens When A Biotech Stock Blows Up: How Our Hedged Portfolio Method Limited The Damage With Cassava Sciences
September 11, 2021
Screen capture via Cassava Sciences' video for their Simulfilam Alzheimer's disease treatment. When A Biotech Stock Goes The Wrong Way In our last post (Corona Doom...
Via
Benzinga
When A Biotech Stock Blows Up
September 11, 2021
How to limit the damage when something goes wrong. We can't always be right, which is why we hedge..
Via
Talk Markets
Cassava Sciences Stock Still Poses Risks After Absorbing Data Controversy
September 09, 2021
Simufilam's eventual approval is still uncertain. Its fading popularity among the Reddit set is a concern as well. Even after it 57%+ price haircut, approach SAVA stock cautiously.
Via
InvestorPlace
Topics
Fraud
Exposures
Legal
Better Buy: Biogen vs. Cassava Sciences
September 04, 2021
These two biotechs are going after a significant market: Alzheimer's.
Via
The Motley Fool
Cassava Plummets — Again — After CEO Denies Data Manipulation Claims
September 03, 2021
Cassava CEO Remi Barbier denied allegations of data manipulation in the firm's Alzheimer's research on Friday. But SAVA stock tumbled, again.
Via
Investor's Business Daily
Cassava CEO Goes Offensive Over Data Allegations
September 03, 2021
Cassava Sciences Inc (NASDAQ: SAVA) has garnered attention recently after a citizen petition with the FDA suggested that the use of Alzheimer's candidate data is based...
Via
Benzinga
Exposures
Product Safety
Fraud Allegations Are Unlikely to Keep Cassava Stock Down
September 03, 2021
Cassava's unchallenged safety and cognition data will result in the FDA allowing it to conduct a Phase 3 trial. SAVA stock is a buy.
Via
InvestorPlace
Topics
Fraud
Exposures
Legal
Product Safety
Cassava Sciences Stock Will Fall Further on Data Manipulation Allegations
September 02, 2021
SAVA stock is still one of the best performers this year, but the recent allegations mean shares will fall further as the story develops.
Via
InvestorPlace
Here's How You Handle a Volatile Stock Like Cassava Sciences
September 02, 2021
Investing in biotech stocks can pay off big, but only if their research pans out. Pay attention to the risk-reward ratio -- and control your greed.
Via
The Motley Fool
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
September 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Abbott Laboratories (NYSE:...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
September 01, 2021
Gainers Neuronetics (NASDAQ:STIM) stock rose 16.51% to $7.83 during Wednesday's regular session. As of 12:30 EST, this security is trading at a volume of 675.7K shares...
Via
Benzinga
Wait to See How the Cassava Sciences Allegations Pan Out
August 31, 2021
Allegations have been leveled against Cassava Sciences. SAVA stock has fallen by more than 50% as a result. Is this a buy-on-the-dip moment?
Via
InvestorPlace
Insiders Like Cassava Sciences, Which Might Be Good News
August 30, 2021
Insider transactions have historically proven quite prescient for the trajectory of SAVA stock, so what do they imply today?
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
August 30, 2021
Gainers Valneva (NASDAQ:VALN) stock moved upwards by 29.61% to $49.9 during Monday's regular session. Valneva's stock is trading at a volume of 143.0K shares as of...
Via
Benzinga
< Previous
1
2
...
12
13
14
15
16
17
18
19
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.